A Phase III Study to Assess the Safety, Tolerability, and Efficacy of MK0822 (Odanacatib) in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 17 Aug 2016
At a glance
- Drugs Odanacatib (Primary)
- Indications Cancer metastases; Prostate cancer
- Focus Registrational; Therapeutic Use
- Sponsors Merck & Co
- 11 Aug 2016 Planned End Date changed from 1 Aug 2008 to 1 Sep 2008.
- 11 Aug 2016 Planned primary completion date changed from 1 Aug 2008 to 1 Sep 2008.
- 21 Jul 2012 Additional trial location (United Kingdom) added as reported by European Clinical Trials Database.